We apply our novel AI based platform to small molecule chemical design challenges to increase speed and success while reducing the cost
United States of America based
- Operations Service
- Own Drug Discovery Programs
- Small molecules
- Preclinical Development
No mentions found
Posts Mentioning This Company
Artificial intelligence (AI) for drug discovery
Cloud-based computation for drug discovery projects using AI
Our platform offers cloud-scale artificial intelligence support for every design decision at each stage of drug discovery. Computational contract research …
No services posted yet
No clinical trials found
- WO2018049328 (from 2018-03-15), Bicyclic compounds useful as gpr120 modulators
- WO2018049324 (from 2018-03-15), Monocyclic compounds useful as gpr120 modulators
- WO2012078519 (from 2012-06-14), 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2
- WO2011031740 (from 2011-03-17), Antibacterial fluoroquinolone analogs
- WO2011031743 (from 2011-03-17), Antibacterial fluoroquinolone analogs
- WO2011031744 (from 2011-03-17), Antibacterial fluoroquinolone analogs
- WO2011031745 (from 2011-03-17), Antibacterial fluoroquinolone analogs
- WO2009137130 (from 2009-11-12), Antibacterial fluoroquinolone analogs
- WO2007051065 (from 2007-05-03), Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
- WO2006065950 (from 2006-06-22), Modeling biological effects of molecules using molecular property models
- WO2006028524 (from 2006-03-16), Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
- WO02059755 (from 2002-08-01), Rdx enhancement of system and method for implementing reusable data markup language (rdl)
- WO0072197 (from 2000-11-30), Reusable data markup language
- WO0161568 (from 2001-08-23), Rdl search engine
- 31000801 (from 2019-04-20), Opportunities and challenges using artificial intelligence in ADME/Tox.
- 29863875 (from 2018-06-05), Geometric Deep Learning Autonomously Learns Chemical Features That Outperform Those Engineered by Domain Experts.
- 31080887 (from 2018-01-01), Wanted: Class VI Antiarrhythmic Drug Action; New Start for a Rational Drug Therapy.
- 26020786 (from 2015-05-29), Summary of the DREAM8 Parameter Estimation Challenge: Toward Parameter Identification for Whole-Cell Models.
- 22560567 (from 2012-05-09), Discovery of XL413, a potent and selective CDC7 inhibitor.
- 19685583 (from 2009-08-18), Building today's platform company.
Assets (therapeutic products)
No assets found
|Year||Partner||Focus||Amount of Deal|
(2011, Jan. 1)
|Boehringer Ingelheim Pharmaceuticals||--||--|
(2012, Jan. 1)
(2017, Jan. 1)
(2019, Jan. 1)
|Lundbeck Pharmaceuticals||Identification of clinical candidates for the treatment of disorders in the central nervous system, including depression, psychosis, seizure and neurodegenerative disorders.||--|